Immunai, a pioneering startup dedicated to constructing a foundational model of the human immune system, has significantly expanded its oncology collaboration with pharmaceutical giant AstraZeneca for the third time. This latest agreement, extending Immunai’s advanced AMICA-OS platform deeper into AstraZeneca’s extensive clinical development pipeline, positions Immunai to receive up to $37.5 million over 2026 and 2027. The renewed commitment underscores the escalating reliance of major pharmaceutical companies on cutting-edge artificial intelligence and multi-omics capabilities to navigate the complexities of modern drug discovery and development.
A Partnership Forged in Innovation: The Evolving Collaboration
The synergistic relationship between Immunai and AstraZeneca commenced in late 2022, though its genesis can be traced back to the challenges and accelerated scientific collaborations spurred by the global pandemic. Noam Solomon, CEO of Immunai, revealed in a recent interview that the companies have maintained a dialogue for approximately five years, indicating a long-standing mutual interest in leveraging advanced immunological insights.
Initially, the collaboration was primarily centered on oncology clinical programs, a critical area given the immune system’s pivotal role in cancer progression and treatment response. The success of these early efforts quickly paved the way for a substantial broadening of scope. By October 2025, the partnership had expanded into Inflammatory Bowel Disease (IBD), a move that Solomon highlighted as reflecting Immunai’s burgeoning interest in extending its platform to multiple therapeutic indications. "We started in immune oncology, expanded to other oncology areas, then into immunology and inflammation, and now we’re moving into cardiovascular inflammation, neuroinflammation, and even obesity and diabetes. The common thread is the immune system," Solomon elaborated, illustrating the vast applicability of their immune system foundation model across diverse disease states where immune dysregulation is a key factor. This strategic diversification not only validates Immunai’s technology but also demonstrates AstraZeneca’s intent to apply these advanced analytical capabilities across its broad portfolio.
AstraZeneca operates on an immense scale, employing approximately 95,000 individuals globally and conducting over 100 Phase 3 clinical studies across a spectrum of therapeutic areas including oncology, rare diseases, cardiovascular and metabolic medicine, and respiratory and immunology. Managing a collaborative effort with an organization of this magnitude from a startup perspective is an operationally intensive undertaking. Solomon emphasized the extensive cross-functional engagement: "Over the years, there are many dozens of people on their side and dozens on our side collaborating. We work with multiple groups: people on the AI and data science side, people in translational medicine, people in clinical development. Each group covers different indications and therapeutic areas." This intricate web of collaboration highlights the deeply embedded nature of Immunai’s technology within AstraZeneca’s R&D ecosystem, moving beyond a simple vendor-client relationship to a true strategic partnership.
Immunai’s "High-End Plumbing": Solving Drug Development Bottlenecks
Immunai’s CEO Noam Solomon famously likens his company’s role to that of a "plumber," albeit one specialized in fixing "very expensive plumbing issues." This analogy aptly captures the core challenge Immunai addresses: the pervasive infrastructure bottlenecks that significantly impede the efficiency and speed of drug development. Bringing a single new drug to market is a notoriously arduous and costly endeavor. According to a recent Deloitte estimate, the average cost for top 20 pharmaceutical companies can reach an staggering $2.67 billion. This astronomical figure is driven by high failure rates in clinical trials, the extensive time required for R&D, and the sheer complexity of understanding disease biology and drug mechanisms. Immunai’s "plumbing" aims to streamline these processes, making drug development more predictable and successful.
A central component of this "plumbing" involves sophisticated data manipulation and analysis at an unprecedented scale. Solomon detailed the process: "First, generating a large volume of data from thousands of samples, creating a digital twin of the patients. Then applying our immune profiling and finding the clinical covariates manifesting in the immune system, so our platform can distill clinically meaningful insights from that." This approach moves beyond merely analyzing existing data; it actively generates high-resolution, multi-dimensional data to uncover hidden biological signals.
The pattern observed across Immunai’s partnerships consistently involves pharmaceutical companies presenting complex clinical questions that their internal infrastructure struggles to resolve. These critical queries often revolve around fundamental challenges in clinical development: "Usually those questions involve finding a better way to stratify patients for a clinical trial, identifying a biomarker for a toxic event, determining the optimal combination agent because a monotherapy isn’t producing the right efficacy results, or finding the right dose and schedule," Solomon explained. By providing the tools and insights to answer these questions, Immunai helps de-risk clinical trials, accelerate timelines, and ultimately improve patient outcomes.
The Power of Single-Cell Resolution and Multi-Omics
Many companies in the burgeoning AI pharma market claim to apply artificial intelligence to existing data. Immunai, however, distinguishes itself through a more proactive and fundamental approach. "The signal already exists, but it’s hidden in the clinical patient samples sitting in your biobanks," Solomon stated. "So in every collaboration, the starting point is the same: send us all the samples you have from the clinical trials, to our lab at 430 East 29th Street in New York. The first step is translating those biological specimens into digital data using single-cell multi-omic profiling of the patient’s immune system." This hands-on method of generating bespoke, high-quality data directly from biological samples is a cornerstone of Immunai’s unique value proposition.
In each project, Immunai meticulously analyzes how the immune system responds and changes before and after a therapeutic intervention. Solomon elaborated on the depth of this analysis: "For every patient, think of it as an immune MRI: a profile at single-cell, multi-omic resolution, taken before and after treatment. Each profile is effectively a matrix of about 10,000 cells, and for each cell we have a large measurement containing roughly 37,000 gene expressions, around 75 surface proteins, and VDJ sequencing."
This extraordinary level of resolution allows Immunai’s team to track subtle yet significant changes in the immune system weeks and even months post-treatment. The subsequent step involves correlating these detailed immune profiles with observed clinical endpoints, such as progression-free survival or overall survival. "By correlating immune surrogate endpoints with clinical endpoints, we identify the immunological features relevant to efficacy, resistance, toxicity, and dosing," Solomon explained. This data-driven approach moves beyond traditional aggregate analyses, enabling the identification of specific cellular mechanisms and molecular signatures that dictate treatment success or failure.
Immunai’s proprietary AMICA database currently houses over 300,000 samples, with approximately 50,000 of these processed at single-cell resolution. Solomon passionately argues that the crucial distinction lies not just in scale, but in resolution, where many competitors fall short. He drew an insightful analogy: "A lot of big numbers in this field don’t actually lead to better decisions or better insights because the data was collected without depth. You’ll never be able to see the difference between green and blue. If that’s the distinction you need to make, you’re stuck." This illustrates that while large datasets are valuable, their utility is severely limited if the underlying data lacks the granularity to reveal critical biological differences.
Furthermore, Immunai’s foundation model architecture provides a significant advantage when working with the often-small cohorts provided by pharma partners, sometimes as few as 20 patients. "If you’ve built a foundation model on large-scale data, every new cohort compounds against the others," Solomon noted. "When you get a new cohort, you can resolve the signal." This means that even small, new datasets can be interpreted within the rich context of the vast, high-resolution data already accumulated in the AMICA database, allowing for robust insights that would be impossible with isolated analyses.
Strategic Alliances and Broader Industry Impact
Immunai’s collaboration with AstraZeneca is not an isolated success. The company has forged other significant partnerships that underscore its growing influence in the AI-driven drug discovery landscape. In April 2025, Immunai teamed up with the Parker Institute for Cancer Immunotherapy (PICI) to create what they described as the largest single-cell dataset for real-world immunotherapy research. This monumental effort aggregated data from 3,700 blood samples across 1,070 patients who had received immune checkpoint inhibitors – a class of drugs that have revolutionized cancer treatment but still suffer from variable patient responses. This collaboration is crucial for unraveling the intricate mechanisms behind immunotherapy success and resistance.
Building on this momentum, in January 2026, Bristol Myers Squibb (BMS), another pharmaceutical titan, signed a multi-year partnership with Immunai. This agreement focuses on analyzing clinical immune data to clarify mechanisms of action, identify specific patient subgroups that are most likely to respond to therapies, and ultimately guide critical development decisions. Such partnerships with industry leaders like AstraZeneca and BMS are powerful endorsements of Immunai’s technological capabilities and its potential to significantly accelerate the development of more effective, personalized medicines.
The repeated and expanding engagements from major pharmaceutical companies like AstraZeneca signify a paradigm shift in how drug discovery and development are conducted. The traditional trial-and-error approach, coupled with fragmented data analysis, is increasingly being supplemented, and in some cases, replaced by sophisticated AI-driven platforms like Immunai’s. By providing unparalleled insights into the immune system at a single-cell, multi-omic level, Immunai is empowering drug developers to make more informed decisions, identify optimal patient populations, predict treatment responses, and mitigate adverse events.
The implications of this trend are profound. For pharmaceutical companies, it means a potential reduction in the staggering costs and timelines associated with drug development, leading to higher success rates in clinical trials. For patients, it promises a future of more precise, targeted, and effective therapies, particularly for complex diseases like cancer, autoimmune disorders, and chronic inflammatory conditions where the immune system plays a central role. As Immunai continues to refine its "digital plumbing" and expand its foundational model of the immune system, its impact on the future of medicine is poised to grow exponentially, transforming biological specimens into actionable insights that unlock new frontiers in human health.
